AOD 9604 vs tirzepatide isn't a fair match
They both turn up in weight-loss searches. That doesn't mean the research puts them on equal footing.
Start with what happened in people
AOD 9604 vs tirzepatide sounds like a simple choice between two weight-loss options. The research doesn't give us that tidy choice. It gives us two very different results, from separate studies.
AOD-9604's main obesity trial didn't show significant weight loss over placebo, a dummy treatment. Tirzepatide's human obesity trial did find a weight-loss benefit. Start there.
| Name | What the research tells us | What it doesn't tell us |
|---|---|---|
| AOD-9604 | The main human weight-loss trial missed its goal. | That a promising idea guarantees weight loss. |
| Tirzepatide | Average weight loss was greater than with placebo. | Exactly what will happen to any one person. |
| MOTS-c | Treatment findings come from cells and animals. | Whether giving it to people helps them. |
These aren't results from a trial testing the compounds against each other. We can't turn separate studies into a precise prediction about which would work better for the same person.
Tirzepatide still comes with trade-offs
The tirzepatide trial followed adults with obesity, or overweight with a weight-related health problem, who didn't have diabetes. It ran for 72 weeks, with lifestyle support in all groups. A result from that setting needs to keep those details attached.
Stomach and bowel symptoms were the most common unwanted effects. Some participants stopped treatment because of side effects. Our tirzepatide guide covers both.
Weight loss also doesn't tell us everything about muscle, strength or day-to-day health. Each needs its own evidence.
MOTS-c hasn't crossed the same bridge
FDA's review for its July 2026 meeting found no published human treatment studies of MOTS-c itself. In the exercise paper, researchers measured people's naturally occurring MOTS-c. They gave the peptide to mice, not to those people.
That is worth investigating. It isn't a human treatment result. The MOTS-c page explains the gap.
Combining them needs its own evidence
None of the studies here shows that adding AOD-9604 or MOTS-c to tirzepatide makes treatment safer or more effective. Different ways of working can suggest an experiment. They don't supply its result.
A prescription doesn't fill that gap, either. FDA explains that compounded medicines aren't FDA-approved. Questions about a combination, existing medicines or approved alternatives belong in a conversation with a licensed clinician. Our FAQ can help get that conversation started.